

20 Apr 2022 | Interviews

QUOTED. Monika Paule.

by

Caszyme CEO and 2022 *In Vivo* Rising Leader Monika Paule is on a mission to expand the CRISPR toolbox of available proteins to enhance diagnostic tools, therapeutics and even agricultural practices.

“Compared with the more common lateral flow test or serology-based diagnostic tools, CRISPR-based diagnostics offer the benefits of greater precision and improved timescales.” – Monika Paule, CEO, Caszyme

- Find out more: [Caszyme CEO Says CRISPR Gene Editing Could Help Patients, Save The Planet](#)

[Click here](#) for a free trial of *Medtech Insight*